# Advisor Review - Gemini-3-Flash

**Role:** Academic advisor checking for fatal errors
**Model:** gemini-3-flash-preview
**Paper:** paper.pdf
**Timestamp:** 2026-02-03T23:00:59.822922
**Route:** Direct Google API + PDF
**Tokens:** 28198 in / 806 out
**Response SHA256:** 4e0e73af7b769d07

---

I have reviewed the draft paper "State Insulin Copay Cap Laws and Diabetes Mortality: A Difference-in-Differences Analysis" for fatal errors.

### 1. DATA-DESIGN ALIGNMENT
*   **Treatment timing vs. data coverage:** The paper claims to study the effect of insulin copay caps using mortality data through 2023. Table 2 (page 14) and Table 11 (page 47) clearly show that the author has identified 8 states with treatment onset in 2024–2025 (GA, IN, LA, MT, NE, NC, OH, WY) and reclassified them as not-yet-treated/controls. The "effectively treated" sample is limited to 17 states with onset $\leq$ 2023. This is an appropriate handling of data truncation.
*   **Post-treatment observations:** The author verifies in the text (page 12) and Table 1 (page 13) that there are 44 observations in the "Treated (Post)" cell, confirming the existence of post-treatment data for the 17-state treated cohort.
*   **Consistency:** The definition of "first treatment year" (first full calendar year of exposure) is applied consistently across the descriptive tables and the regression analysis.

### 2. REGRESSION SANITY
*   **Standard Errors:** Table 3 (page 21) and Table 5 (page 28) show standard errors for mortality rates (deaths per 100,000) ranging from 1.3 to 3.4. Given a mean outcome of ~22-25, these SEs are within a normal, plausible range. No SEs exhibit the massive magnitudes associated with collinearity artifacts.
*   **Coefficients:** Coefficients for mortality rates are generally small (e.g., -0.242, 1.208). The log-specification in Table 3, Column 3, shows a coefficient of 0.050, which is a plausible ~5% change. No coefficients exceed the fatal error thresholds ($>10$ for log outcomes or $>100$ for levels).
*   **Impossible Values:** $R^2$ values in Tables 3 and 5 are between 0.4 and 0.8, which is normal for state-level panels with fixed effects. No negative standard errors or "Inf/NaN" values were detected in any regression results.

### 3. COMPLETENESS
*   **Placeholders:** No "TBD", "PLACEHOLDER", or "XXX" strings were found. Tables appear fully populated.
*   **Missing Elements:** All regression tables (Tables 3, 5, 10, 12) include Sample Sizes (N) and Standard Errors/Confidence Intervals.
*   **References:** All cited tables (including appendix tables 7-13) and figures (1-10) exist and are properly labeled within the document.

### 4. INTERNAL CONSISTENCY
*   **Numbers Match:** The aggregate ATT of 1.524 cited in the text (page 20) matches the value reported in Table 10 (page 46).
*   **Timing Consistency:** The treatment cohorts and state counts (17 treated, 34 control) match between the text (page 4), Table 2 (page 14), and the summary statistics in Table 1 (page 13).
*   **Controls:** The specification for COVID controls (rescaling death counts to rates per 100,000) is consistent between the text (page 21) and the robustness tables.

**ADVISOR VERDICT: PASS**